|Bid||121.64 x 1400|
|Ask||131.99 x 1300|
|Day's Range||128.67 - 129.63|
|52 Week Range||111.36 - 136.83|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.
As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.
As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter. Of the 21 analysts tracking Bluebird Bio, five recommend “strong buy,” nine recommend “buy,” six recommend “hold,” and one recommends “sell.”
Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018, compared to estimates for EPS of $3.67 on revenues of $3.8 billion.
Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq ...
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.
BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.
Headquartered in Ireland, Allergan (AGN) develops, manufactures, and commercializes pharmaceutical products and devices, as well as biologic products. On April 30, Allergan reported 2.8% revenue growth to ~$3.7 billion in 1Q18, compared to revenues of ~$3.6 billion in 1Q17. The chart below shows Allergan’s revenues since 1Q17.
Pharmaceutical giant Allergan (AGN) is set to release its 1Q18 earnings on April 30. Wall Street analysts estimate that the company could report earnings per share (or EPS) of $3.36 on revenues of $3.6 billion for 1Q18.
The fourth-quarter earnings season is expected to be strong, with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter. The S&P 500 index is anticipated to see earnings growth of 9.2% and revenue growth of 7%. The market is also at record levels, scaling series of highs at the start of the year.Source: Shutterstock
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.
VanEck announced today the following 2017 annual distributions per share for its VanEck Vectors® equity exchange-traded funds.
VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.
Gilead Sciences' (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver diseases, oncology, cardiovascular, inflammation, respiratory, and others.
Daniel Schwartz, York Capital Management co-CEO, weighs in on the strength of the M&A market and where he sees the biggest opportunities, including biotechnology and the telecom industry.